卡培他滨联合奥沙利铂治疗对进展期胃癌患者血清Th1和Th2类细胞因子的影响

The Effect of Capecitabine Combined with Oxaliplatin Treatment on Serum Th1/Th2 Cytokines in Treatment of Patients with Advanced Gastric Cancer

目的观察卡培他滨联合奥沙利铂治疗对进展期胃癌患者血清Th1、Th2细胞因子的影响。方法对107例进展期胃癌患者采用XELOX治疗方案,即奥沙利铂130 mg·m-2,iv,d1、d15;卡培他滨2000 mg·m-2,2次/d,d1~d14;28 d为1个化疗周期,连续治疗3个周期。按照WHO实体肿瘤近期客观疗效评定标准进行评价。采用ELISA法检测化疗前后胃癌患者外周血血清中IL-2、IFN-γ、TNF-β以及IL-4、IL-6、IL-10的表达水平。结果与化疗前相比,患者Th1型细胞因子表达水平均有明显升高(P<0.05);Th2型细胞因子表达水平显著降低(P<0.05);临床疗效与各细胞因子之间有明显关联(P<0.05),其中IFN-γ和IL-4的关联程度最高,Pearson相关系数分别为0.75和-0.83。结论卡培他滨联合奥沙利铂化疗可降低胃癌患者Th2类细胞因子的表达水平,该作用趋势可能与化疗抑制肿瘤的生长、对机体后期的转归、康复有关。

Objective To observe the effect of capecitabine combined with oxaliplatin on serum Thl/Th2 cytokines for treatment of advanced gastric cancer patients, Methods 107 patients with advanced gastric cancer were treated with XELOX regimen： oxaliplatin 130 mg.m-2, iv, d1, d15; capecitabine 2000 mg.m-2, bid, d1-d14; 28 days for the 1 chemotherapy cycles and the continuous use time was 3 cycles. The recent objective evaluation for solid tumor was in accordance with WHO criteria and the expressions of Th 1/Th2 cytokines in peripheral blood of patients with gastric cancer before and after chemotherapy were detected by ELISA. Results The level of Thl cytokine expression after chemotherapy significantly increased compared with that before chemotherapy and the difference was statistically significant （P〈0.05）. The level of Th2 cytokine expression after chemotherapy significantly decreased compared with that beibre chemotherapy and the difference was statistically significant （P〈0.05）. It had a clear association between clinical efficacy and the various cytokines （P〈0.05）, among which IF and IL-4 cell had the closest association, and the Pearson correlation coefficient were 0.75 and -0.83. Conclusions Capecitabine combined with oxaliplatin chemotherapy could decrease the level ofTh2 cytokines in peripheral blood, which may be related to the inhibition of tumor growth, the prognosis and the rehabilitation of the body.